Please login to the form below

Not currently logged in
Email:
Password:

MRC Technology and Peptinnovate join on bone disease

Firms aim to discovery a therapy using natural peptides 

Pharmaceutical research and developmentIndependent medical research charity MRC Technology has teamed up with Peptinnovate to assess potential therapies in bone diseases.

Peptinnovate, which is developing first-in-class disease modifying medicines for immuno-inflammatory diseases, will investigate its unique peptides derived from the bacterium mycobacterium tuberculosis, the pathogen that causes TB.

Natural peptides from the pathogen are able to modify the immunological and inflammatory response in humans. Peptinnovate is investigating whether the properties could form the basis of new medicines for a variety of disease indications that involve altered immune responses.

Andrew Lightfoot, CEO, Peptinnovate, said: “We are delighted to be working with experts at MRC Technology to better understand the potential of our approach in the treatment of bone diseases, our second area of therapeutic focus. 

“Peptinnovate is continuing to develop strongly, following on from our recent Biomedical Catalyst funding success, which stands us in good stead for future fundraising and partnering.”

The collaboration is a result of interaction by Stevenage Bioscience Catalyst, where Peptinnovate is based and MRC Technology is relocating next year.

Martino Picardo, CEO at Stevenage Bioscience Catalyst, added: “This partnership is just the kind of interaction Stevenage Bioscience Catalyst was established to facilitate and drive. 

“It's great to see this collaboration between one of our first and one of our newest tenants, and we hope to see many more fruitful relationships as the campus continues its rapid development.”

Article by
Kirstie Pickering

10th June 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...